EUVIMEDEUVIMED entdecken
Crossref

Gut Microbiota and Bile Acid Metabolism in the Mechanism of Ginsenoside Re Against Nonalcoholic Fatty Liver Disease

Yanfang Zheng iD, Jiaying Chen, Ying Zhang, Huaying Guan, Shan Deng, Dennis Chang, Yitao Wang, JinJian Lu, Xian Zhou iD, Qin Xie, Jianyuan Song, Mingqing Huang

Phytotherapy Research · 2025

DOI: 10.1002/ptr.8474 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytotherapy Research, 2025. Verfasst von Yanfang Zheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated People's Hospital, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Non-alcoholic Fatty Liver Disease, Bile Acids and Salts, Ginsenosides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Key Research and Development Program of China Stem Cell and Translational Research, Collaborative Innovation Platform Project of Fuxiaquan National Innovation Demonstration Zone, National Natural Science Foundation of China Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gut microbiota and bile acid metabolism play crucial roles in the progression of nonalcoholic fatty liver disease (NAFLD). Early evidence demonstrates that Ginsenoside Re (Re) possesses pharmacological effects on NAFLD, but its mechanisms of action are not well understood. This study aimed to investigate the hepatic protective effects of Re in NAFLD and elucidate relevant mechanisms. The effects of Re treatments (10, 20, or 40 mg/kg) against high‐fat diet‐induced NAFLD were initially tested on male C57BL/6 mice. Then, a separate mouse group received Re with or without antibiotics to confirm the regulatory role of microbiota in the effect of Re. Finally, another group of mice received fecal microbiota transplantation (FMT) from the initial experiment of NAFLD mice to further investigate the mechanistic role of gut microbiota. Re significantly improved liver function by reducing hepatic lipid accumulation, injury and hepatocyte steatosis, and inflammation. The liver protection was mediated by the regulation of gut microbiota as evidenced by restored intestinal barrier integrity, normalized Firmicutes/Bacteroidota ratio, enhanced abundances of Adlercreutzia equolifaciens , and reduced Faecalibaculum rodentium . Following that, Re reduced total and primary bile acids and downregulated bile acid synthesis genes and proteins such as farnesoid X receptor and cytochrome P450 family 7 subfamily A member 1. The co‐administration of antibiotic cocktail counteracted the effect of Re against NAFLD. Further, the results obtained from the FMT animal study confirmed that Re's liver protective effects were at least partly driven by the regulation of gut microbiota. Re modulated bile salt hydrolase‐related microbial genera to alter bile acid synthesis pathways, thereby inhibiting NAFLD progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeNon-alcoholic Fatty Liver DiseaseBile Acids and SaltsGinsenosidesAnimalsMaleMice, Inbred C57BLMiceDiet, High-FatLiverFecal Microbiota Transplantation

Stichwörter der Autor:innen

Firmicutes/BacteroidotaGinsenoside Rebile acidsgut microbiotaintestinal barrier integritynonalcoholic fatty liver disease

Substanzen

Bile Acids and SaltsGinsenosidesginsenoside Re

Autor:innen und Institutionen

  • The Affiliated People's Hospital, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, China.
  • NICM Health Research Institute, Western Sydney University, Westmead, New South Wales, Australia.
  • State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau, China.
  • Department of Stomatology, Fujian Medical University Union Hospital, Fuzhou, China.
  • Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, China.

ORCID-Profile: Yanfang Zheng, Xian Zhou

Förderung

  • National Key Research and Development Program of China Stem Cell and Translational Research
  • Collaborative Innovation Platform Project of Fuxiaquan National Innovation Demonstration Zone
  • National Natural Science Foundation of China Projects
  • Research Support Program Fellowship, Western Sydney University

Zitieren

APA

Zheng, Y., Chen, J., Zhang, Y., Guan, H., Deng, S., Chang, D., Wang, Y., Lu, J., Zhou, X., Xie, Q., Song, J., & Huang, M. (2025). Gut Microbiota and Bile Acid Metabolism in the Mechanism of Ginsenoside Re Against Nonalcoholic Fatty Liver Disease. Phytotherapy Research. https://doi.org/10.1002/ptr.8474

Vancouver

Zheng Y, Chen J, Zhang Y, Guan H, Deng S, Chang D, et al. Gut Microbiota and Bile Acid Metabolism in the Mechanism of Ginsenoside Re Against Nonalcoholic Fatty Liver Disease. Phytotherapy Research. 2025. doi:10.1002/ptr.8474

BibTeX
@article{Zheng2025,
  author = {Zheng, Yanfang and Chen, Jiaying and Zhang, Ying and Guan, Huaying and Deng, Shan and Chang, Dennis and Wang, Yitao and Lu, JinJian and Zhou, Xian and Xie, Qin and Song, Jianyuan and Huang, Mingqing},
  title = {Gut Microbiota and Bile Acid Metabolism in the Mechanism of Ginsenoside Re Against Nonalcoholic Fatty Liver Disease},
  journal = {Phytotherapy Research},
  year = {2025},
  doi = {10.1002/ptr.8474}
}
Kostenlos starten →